Media stories about Depomed (NASDAQ:DEPO) have been trending somewhat positive on Friday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Depomed earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 45.6162431985821 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the news articles that may have impacted Accern Sentiment’s analysis:

Depomed (DEPO) opened at $6.30 on Friday. Depomed has a 1 year low of $4.31 and a 1 year high of $21.38. The company has a quick ratio of 0.79, a current ratio of 0.83 and a debt-to-equity ratio of 2.90.

Depomed (NASDAQ:DEPO) last issued its quarterly earnings data on Tuesday, November 7th. The specialty pharmaceutical company reported $0.14 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.02. The firm had revenue of $95.40 million for the quarter, compared to analyst estimates of $99.11 million. Depomed had a negative return on equity of 51.07% and a negative net margin of 27.73%. The business’s quarterly revenue was down 13.7% compared to the same quarter last year. During the same period last year, the company earned $0.28 EPS. analysts predict that Depomed will post -1.34 earnings per share for the current year.

Several equities analysts recently issued reports on the company. Morgan Stanley lowered Depomed from an “equal weight” rating to an “underweight” rating and reduced their price target for the stock from $12.00 to $5.00 in a research report on Tuesday, August 8th. Royal Bank Of Canada set a $10.00 price target on Depomed and gave the stock a “hold” rating in a research report on Friday, October 20th. Piper Jaffray Companies restated a “hold” rating and set a $9.00 price target on shares of Depomed in a research report on Sunday, September 10th. UBS Group AG raised their price target on Depomed from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Friday, November 10th. Finally, Janney Montgomery Scott lowered Depomed from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $18.00 to $8.00 in a research report on Tuesday, August 8th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $10.64.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at

Depomed Company Profile

Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).

Insider Buying and Selling by Quarter for Depomed (NASDAQ:DEPO)

Receive News & Stock Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related stocks with our FREE daily email newsletter.